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Abstract Decision makers increasingly request evidence
on the real-world cost effectiveness of a new treatment. There
is, however, a lack of practical guidance on how to conduct an
economic evaluation based on registry data and how this
evidence can be used in actual decision making. This paper
explains the required steps on how to perform a sound eco-
nomic evaluation using examples from an economic evalu-
ation conducted with real-world data from the Dutch
Population basedHAematological Registry for Observational
Studies. There are three main issues related to using registry
data: confounding by indication, missing data, and insuffi-
cient numbers of (comparable) patients. If encountered, it is
crucial to accurately deal with these issues to maximize the
internal validity and generalizability of the outcomes and
their value to decision makers. Multivariate regression
modeling, propensity score matching, and data synthesis are
well-established methods to deal with confounding. Multiple
imputation methods should be used in cases where data are
missing at random. Furthermore, it is important to base the
incremental cost-effectiveness ratio of a new treatment
compared with its alternative on comparable groups of
(matched) patients, even if matching results in a small ana-
lytical population. Unmatched real-world data provide
insights into the costs and effects of a treatment in a real-
world setting. Decision makers should realize that real-world
evidence provides extremely valuable and relevant policy
information, but needs to be assessed differently compared
with evidence derived from a randomized clinical trial.
Key points for decision makers
Outcomes of economic evaluations based on registry
data are to be assessed differently than economic
evaluations based on trial data
Frequently encountered issues, such as confounding
by indication, missing values, and insufficient
number of comparable patients, need to be
adequately addressed to maximize the internal
validity
Real-world data provide generalizable outcomes and
provide insights into a drug’s value for money in
daily practice
1 Introduction
Considerations of costs and cost effectiveness are
increasingly important for decision making on healthcare
resource allocation. Economic evaluations enable a com-
parison of the cost-effectiveness of alternative treatments,
and are thus especially important for decision making on
reimbursement of new expensive drugs. Until recently,
economic evaluations mainly consisted of cost-effective-
ness analyses (CEAs) modeled from randomized clinical
trial (RCT) data. RCTs aim to demonstrate the efficacy of
interventions and ensure internal validity by randomly
assigning which patients receive the new intervention. The
circumstances in especially phase III trials are, however,
not generalizable (i.e., externally valid) to a more hetero-
geneous group of patients treated in a real-world setting.
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Therefore, many uncertainties remain regarding the rele-
vance of the results of RCTs in a real-world setting.
Cost-effectiveness evidence based on RCT data may,
therefore, not be sufficiently informative for decision
makers. In such cases, evidence needs to be obtained from
other sources, for example patient registries. A patient
registry enables the evaluation of specified outcomes for a
population defined by a particular disease, condition, or
exposure, and when thoroughly designed and performed a
patient registry can provide real-world evidence of clinical
practice, patient outcomes, safety, and comparative effec-
tiveness [1].
Guidelines on conducting and reporting economic
evaluations are readily available [2–4], as well as ques-
tionnaires to assess the relevance and credibility of
observational studies [5]. However, barriers still exist to
use evidence from economic evaluations in actual deci-
sion making [6, 7]. This necessitates the evaluation of the
strengths and limitations of different types of evidence
[8]. Moreover, practical guidance on using registry data
for economic evaluations as well as on how these eval-
uations can be used in decision making is currently
lacking.
This paper presents a practical guide on how to use
registry data to inform decisions about the cost effective-
ness of new drugs. We discuss the required steps of con-
ducting a sound economic evaluation; the steps are
explained by using the Population based HAematological
Registry for Observational Studies (PHAROS) as an
example. Although using registry data imposes some
challenges, we illustrate that it is feasible to conduct an
economic evaluation. We also discuss potential issues and
limitations of economic evaluations based on registry data.
The last section highlights the value of real-world eco-
nomic evaluations for decision makers.
2 PHAROS and Its Context
In the Netherlands, outcomes research requirements were
implemented in 2006 for new expensive drugs to ensure
timely access to promising drugs. If a drug is included in
this policy, hospitals receive an additional ear-marked
budget; however, with the obligation to gather data on
appropriate drug use and real-world cost-effectiveness [9,
10]. A reassessment after 4 years determines whether or
not additional financing will continue. Real-world data are
often collected within a patient registry.
One of the first Dutch patient registries was PHAROS.
PHAROS is a population-based disease registry that star-
ted in 2010 with three hematologic malignancies (non-
Hodgkin lymphoma, multiple myeloma, and chronic
lymphatic leukemia) in three regions; these regions cover
40 % of the Netherlands [11]. PHAROS expanded over
the years to other hematological malignancies (chronic
myeloid leukemia, myelodysplastic syndromes, and mye-
lofibrosis) and is currently expanding to a nationwide
coverage. Like many other registries, PHAROS was cre-
ated to serve multiple purposes including measuring and
improving the quality of care and determining the clinical
and cost effectiveness of treatments used in a real-world
setting. This paper uses examples of the economic eval-
uation [12] based on data from PHAROS. This economic
evaluation was conducted to inform the reassessment of
rituximab maintenance therapy for patients with follicular
lymphoma, a subtype of non-Hodgkin lymphoma. A Mar-
kov Model was used with a 20-year time horizon to
compare rituximab maintenance therapy in patients who
responded to second-line chemotherapy with best sup-
portive care (i.e., observation after a response to second-
line chemotherapy). For further details we refer to
Blommestein et al. [12].
3 Conducting Sound Economic Evaluations
with Registry Data
Economic evaluations typically include a number of steps,
irrespective of the source of data. These steps, comprising
existing guidelines in academic literature [2–4] are pre-
sented in Table 1.
Table 1 Steps of an economic evaluation
Step Description
Policy issue Define the objective of the economic
evaluation and ascertain its relevance for
healthcare decision making
Research question Determine the main research questions
(including what is studied for whom)
Perspective Define the perspective of the study
Comparator Identify the relevant alternative
treatment(s)
Identify, measure,
and value costs
Identify the relevant costs and measure
these costs and value the unit costs
Identify, measure,
and value outcomes
Identify the relevant outcomes and
measure and value these outcomes
Calculate the cost-
effectiveness ratio
Obtain the incremental costs and effects
and calculate the incremental cost-
effectiveness ratio
Sensitivity analyses Analyse the uncertainty of the outcomes
using deterministic, probabilistic, and
scenario analysis
Presentation and
discussion of results
Present the results and discuss all issues of
concern
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3.1 The Policy Issue
Above all, it is important to define a clear objective for the
economic evaluation and ascertain its relevance to health-
care decision making. One of the reasons to initiate
PHAROS was to support decision making on the reim-
bursement of expensive drugs for three hematologic
malignancies. Consequently, PHAROS data should facili-
tate the conduction of economic evaluations with real-
world data.
3.2 Define the Research Question
It is crucial to determine the main research questions of the
economic evaluation before setting up a registry that should
collect the required data. For example, if a registry needs to
be able to answer questions about the incremental cost-
effectiveness ratio (ICER), relevant costs, and effects of at
least two groups of patients are to be collected. Decision
makers in the Netherlands require real-world evidence on
appropriate use, effectiveness, and incremental cost effec-
tiveness of drugs. Based on these requirements, the fol-
lowing research questions were defined for PHAROS:
i) To whom and how is the drug of interest prescribed
in daily practice?
ii) What is the real-world effectiveness of this drug?
iii) What is the real-world incremental cost effectiveness
of this drug?
Regarding the first research question, PHAROS needed
to include detailed data on baseline patient characteristics
(including prognostic information) of patients who were
treated as well as of patients who were not treated with the
drug of interest. While a registry can be intervention based,
PHAROS was set up as a disease-based registry. The
advantage of using a disease-based registry is that all
patients are included who meet the disease criteria.
Therefore, PHAROS included patients eligible for treat-
ment as well as patients ineligible for treatment. This also
enabled identifying patients eligible for treatment but not
treated with the drug of interest; these patients may serve as
a comparator group. In addition, PHAROS needed to
provide evidence on how drugs were used in daily practice.
PHAROS not only included data on types of treatment, but
also data on treatment regimes, dosages, dose modifica-
tions, treatment interruptions, and treatment duration.
Furthermore, from a policy perspective, it is important to
obtain insight into equitable access to (expensive) drugs.
Population-based registries can serve to obtain evidence on
uptake by hospital and region; they may thus serve to
reveal differences in access to a drug between regions and
between university and general hospitals. In cases where
data are based on a non-population-based registry, it is
crucial that the selection is representative for the entire
patient population as well as that a sufficient number of
patients is included to ensure generalizability.
Regarding the second research question, PHAROS had
to provide evidence on real-world effectiveness of the drug
of interest. RCTs are the gold standard to demonstrate
efficacy and assure internal validity by random assigning
patients to a treatment strategy. In contrast, registries
involve observational data and provide details on patients
treated in daily practice. Reimbursement decisions may
depend on the real-world use, effectiveness, and costs; in
cases where a drug is not effective or not cost effective in
daily practice, reimbursement of the drug may be recon-
sidered. If well designed, a registry includes information
that enables accounting for heterogeneity in daily practice
patients, physician variation, and the healthcare context.
Therefore, effectiveness estimates based on registry data
assure external validity and are thus generalizable to the
real-world patient population. Ideally, the data should
cover all treatments from diagnosis until death. However,
this also depends on the length of follow-up and the time an
analysis is required for policy making.
Regarding the third research question, PHAROS data
needed to be able to demonstrate incremental real-world
cost effectiveness of the drug of interest. Similarly to the
second research question, a well-designed disease registry
enables the estimation of incremental real-world effects,
costs, and cost effectiveness simultaneously.
3.3 Define the Perspective of the Study
The perspective of the economic evaluation determines what
type of costs and outcomes are to be included in the analyses.
Most economic evaluations are conducted from a third-party
payer or societal perspective. A societal perspective implies
the inclusion of all relevant costs (direct and indirect,
medical and non-medical costs) and relevant outcomes
(quality of life and life-years). In contrast, in a third-party
payer perspective non-medical costs are not included (e.g.,
traveling costs, productivity costs). Other used perspectives
are healthcare, hospital, and patient. Requirements regard-
ing the perspective may differ per country. It is, however,
best to define the perspective before the start of data col-
lection because it determines what costs and outcomes are
needed for the economic evaluation. The objective of
PHAROS was to gather evidence for the reassessment of
expensive drugs in the Netherlands. Such a reassessment
requires a societal perspective in the Netherlands.
3.4 Identify the Comparator(s)
Economic evaluations involve a ‘‘comparative analysis of
alternative courses of action in terms of both their costs and
A Practical Guide for Using Registry Data 553
consequences’’ [2]. The choice of comparator is crucial for
the outcomes of the economic evaluation and it may
potentially be a source of bias. In economic evaluations
based on real-world data, it may not always be clear which
alternative treatment is the most appropriate comparator
and it may depend on the policy issue at stake. The most
relevant alternative for decision makers is usually the
current standard of treatment, this may also be best sup-
portive care or a wait-and-see policy [12]. The inclusion of
control groups to a registry adds to its complexity, time,
and costs [1], but it allows the performance of a sound
economic evaluation that compares a new treatment with
the current standard of care. Collecting data over a long
time period increases the chance that a registry includes an
appropriate comparator group and avoids incomparable
patient groups because of for example a rapid uptake of a
new drug. This was, for example, illustrated by a Dutch
observational study among patients with stage III colon
cancer. Patients ineligible for the drug of interest had
higher levels of unfavorable prognostic factors, i.e., carci-
noembryonic antigen levels at baseline [13]. PHAROS
included patients diagnosed from 2004 to 2012 and inclu-
ded relatively more patients in the comparator group who
were included in the earlier years of the registry, while the
intervention group included more patients who were
diagnosed at the later years of the registry.
3.5 Identify, Measure, and Value Relevant Costs
Costs can be identified in the following categories; hospital
resources, community care resources, patient and family
resource use, and resource use in other sectors [2].
Guidelines regarding economic evaluations and valuation
of unit costs can differ per country, as can the available
data. We used Dutch data and the methods as set forward
by Dutch guidelines [14].
Relevant cost items for inclusion in the registry depend
on disease characteristics, the patient population, treatment
strategies of interest, and the perspective of the study. It is
usually not efficient to collect all potential cost components
and a balance needs to be established between the rele-
vance of the cost item relative to the burden of collection
[1]. This balance can be based on previous research find-
ings and/or determined in collaboration with treating phy-
sicians and based on professional guidelines. In PHAROS,
data on hospital resource use were collected for outpatient
visits, daycare treatment, inpatient days, and intensive care
days. In addition, data on drug dosages, treatment duration,
and supportive care were collected. Data on services pro-
vided outside the hospital were not collected.
Generally, data on hospital resource use can be collected
from electronic hospital records and patient files. However,
data can only be retrieved if it has been adequately reported
by physicians. Adequate reporting may be hampered in
daily practice because physicians are not dictated by strict
criteria as in trials. Patient questionnaires can be used to
collect data on additional direct medical costs (e.g.,
healthcare providers outside the hospital, concomitant
medication), direct non-medical costs (e.g., traveling costs),
and indirect non-medical costs (e.g., productivity costs). It is
important to note, however, that the inclusion of cost items
other than direct medical may be hampered in a registry in
which data are retrospectively collected. In PHAROS, we
encountered several issues. First, information on resource
use outside hospitals was expected to be extremely frag-
mented, especially in cases of severe diseases with cen-
tralized treatment. Patients in the PHAROS registry were
often discharged from hospital and referred to different
rehabilitation centers. Second, although PHAROS was ini-
tiated as a prospective registry, clinical and costs data were
mainly collected retrospectively at several points in time. In
other words, we started in 2010 to collect data from patients
diagnosed from 2004 onwards. Patients were identified
using the nationwide Netherlands Cancer Registry. This
resulted, however, in a delay in the inclusion of patients.
Regarding productivity costs, PHAROS was supple-
mented with information from the Patient Reported Out-
comes Following Initial treatment and Long term
Evaluation of Survivorship (PROFILES) study. This lon-
gitudinal cross-sectional study was conducted to obtain
insight on amongst others quality of life and productivity
losses of patients with follicular lymphoma [15]. However,
the reassessment of the drug of interest was bounded by a
4-year re-evaluation period. At the time, our economic
evaluation needed to be conducted for Dutch decision
makers, the number of patients included in the longitudinal
study was limited and data could not be matched to the
disease states in our model. Therefore, the economic eval-
uation did not include productivity costs. We assumed that
this was a conservative approach because the productivity
costs for rituximab maintenance are most likely lower
compared with the best supportive care group [16, 17].
Furthermore, economic evaluations should only concern
costs related to the disease and/or its treatment instead of
the costs induced by unrelated diseases occurring simulta-
neously. It is important to note, however, that establishing
such a relation is not always easy or clear-cut when using
registry data. For example, admission of older patients to a
nursing home may either be related to the disease but may
also have occurred for other reasons. Moreover, determin-
ing which costs are related to the disease and/or its treat-
ment is even less straightforward for an older population
and in cases where comorbidities are present. Therefore, the
inclusion of some cost items may be debatable.
The inclusion of cost items in the PHAROS economic
evaluation was based on our previous experiences and
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supported by the literature that reported the same main cost
drivers in treating hematologic patients [12, 18]. Therefore,
it was believed that an appropriate balance was achieved
between registration burden and relevance of the cost
items. Such an evaluation of assumptions is crucial and
depends on the characteristics of the patient population and
the type of drug of interest. More detailed information
regarding the included cost items and the unit costs are
reported elsewhere [12].
The definition of the policy issue and research questions
determines the cost components included in a registry. It is
possible that researchers who conduct the economic eval-
uation are not yet involved at the start of the registry and
must therefore rely on available data. In these cases, con-
firmations from the literature should be obtained to ensure
that the most important cost components are included in the
economic evaluation.
3.6 Identify, Measure, and Value Outcomes of Each
Alternative
The most preferred effectiveness outcomes for policy
makers are overall survival (OS)/life-years gained (LYG),
and quality-adjusted life-years (QALYs) but also other
clinical objectives linked to improvement in patients’
outcomes can be included [14]. The follow-up in registries
is generally much longer compared with RCTs and data are
collected on subsequent treatments. Therefore, registries
usually provide more information on OS. In addition, if
data on life-time follow-up are collected, extrapolation of
survival data, associated with uncertainty, is no longer
necessary. Life-time follow-up is extremely valuable for
economic evaluations because a lifetime horizon is usually
required to incorporate all potential differences in effects
and costs for the remainder of the patient’s life [2]. How-
ever, because economic evaluations should provide timely
results, it may be necessary to conduct evaluations prior to
reaching the ideal follow-up time. Regarding other effec-
tiveness outcome measures, it is important to be aware that
they may differ from the endpoints of an RCT. For
example, primary endpoints of RCTs in cancer are most
often response, time to progression, and progression-free
survival; OS rarely is a primary endpoint in an RCT. In
observational registries, however, data on response and
progression may be biased because this may not be accu-
rately captured in patient files [19]. Moreover, physicians
in daily practice often do not report using standardized
response criteria [20], whereas RCTs dictate response cri-
teria. This may especially be the case when data are ret-
rospectively collected by other individuals than the treating
physician. The moment at which progression is established
may also differ from an RCT because there is no strict
monitoring scheme; progression could thus be established
much later than it occurs. Therefore, we advocate using
time-to-next-treatment (TTNT) as a proxy for progression,
additional to survival, in economic evaluations based on
registry data. Whenever a physician changes to another
treatment, there must be a reason for doing so; progression
can be one of them. In PHAROS, we used TTNT to model
final outcomes (i.e., LYG and QALYs).
Regarding the adverse effects of treatments, these
should be accounted for in the economic evaluation.
However, identifying and measuring toxicity data may be
hampered in a registry. Although adverse events and their
severity grading were collected in PHAROS, we encoun-
tered substantial issues establishing causal relations
between the treatment and the adverse event.
Regarding the outcome quality of life, these data can be
collected in a registry using patient-reported outcome
measures. As mentioned previously, the number of patients
included in the PROFILES study was still limited, and we
could not match the data to the disease states in our model.
Therefore, we based the utilities on findings in the literature.
3.7 Calculate the ICER
This step usually involves modeling methods such as
Markov modeling or patient-level simulation modeling
[21]. It is important to carefully select the model that best
fits the data from the registry [22]. This step can greatly
differ from only using data from an RCT. The main issues
in calculating the real-world incremental cost effectiveness
are associated with confounding by indication, missing
data, and insufficient numbers of (comparable) patients.
These issues will be further discussed in the next section.
The ability to deal with these issues determines whether it
is possible to develop a feasible model for the economic
evaluation and to obtain valid incremental estimates based
on real-world data only [19]. We used the methods as set
forward by Dutch guidelines. Detailed information on the
cost-effectiveness calculations performed with PHAROS
data is reported elsewhere [12].
3.8 Assessment of Uncertainty
The outcomes of an economic evaluation are surrounded
with uncertainties, irrespective of whether the economic
evaluation is based on data from an RCT or a registry.
Therefore, it is important to extensively conduct analyses
of the most important uncertainties. This information may
be crucial for deciding on the adoption of a new drug. The
uncertainty of input parameters can be analyzed by sce-
nario analysis as well as probabilistic and univariate sen-
sitivity analyses [2]. In PHAROS, we observed great
patient heterogeneity which resulted, in combination with
small numbers of eligible patients treated with the drug of
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interest, in wide confidence intervals. In addition, as pre-
sented in Table 2, different scenarios based on different
assumptions lead to different cost-effectiveness ratios (e.g.,
costs per QALY ranged from €11,499 to €12,789 to
€23,919 in three scenarios [12]). While information
regarding the assumptions for the model and appropriate
sensitivity analyses on assumptions apply to all economic
evaluations, we believe this is even more important when
using registry data. Assumptions to calculate incremental
outcomes might be because of the absence of randomisa-
tion, which is less straightforward.
3.9 Presentation of the Results and Discussion of All
Issues of Concern to Users
Presenting and discussing the results in an understandable
matter is of utmost importance for the use of economic
evaluations in decision making [6]. This may even be more
important when the economic evaluation is based on data
from registries because registry data are often less
straightforward and more prone to bias. Topics that need to
be reported depend on the conducted economic evaluation
but should at least include: information on confounders,
methods to account for missing values, validity, and gen-
eralizability of the results. The latter two are extremely
important to determine usefulness of the results for deci-
sion makers [2]. It is also important to separately report
both the effects and costs per alternative. Extremely high
ICERs may, for example, indicate large cost differences
between alternatives, but they can also result from small
incremental effects.
4 The Main Issues in Economic Evaluations Based
on Registry Data
There are three main issues with conducting economic
evaluations with real-world data from registries:
(i) confounding by indication; (ii) missing data; and (iii)
insufficient number of patients. If encountered, it is crucial
to appropriately deal with these issues to maximize the
validity of the results of the economic evaluation and its
value to decision makers.
4.1 Confounding by Indication
One of the main concerns about observational data raised
in academic literature is the lack of a randomized con-
trolled setting, which results in problems with internal
validity [23–25]. Instead of treatment being randomly
assigned as in an RCT, the choice of treatment is made by
the treating physician based on characteristics of the
patient. In addition, insurance coverage or national guide-
lines may also influence outcomes [8]. It is important to be
aware that confounding by indication is a major challenge
for economic evaluations based on observational data from
registries. PHAROS showed that the real-world patient
population was highly heterogeneous. When baseline
patient characteristics associated with the outcome of
interest differ between the treatment groups, the results of a
study are biased if not appropriately corrected for these
differences. We are aware that no correction method can
substitute randomization, but there are several methods that
can be used to increase the validity of the outcomes.
Methods to deal with confounding by indication are for
example multivariable regression modeling, propensity
score (PS) matching, and data synthesis. Multivariable
regression modeling has been the conventional method to
reduce bias related to confounding by indication. Potential
confounders are included simultaneously in a regression
model that estimates final outcomes. Using multivariable
regression models for registry data requires information on
patient and disease characteristics.
In the past decade, there has been an increasing trend of
using PS matching techniques [26]. This technique allows
the calculation of the chance of receiving the treatment of
Table 2 Scenario analysis of the PHAROS economic evaluation [12]
Scenarios Data for effects
(cases and controls)
Data for costs
(cases and controls)
ICER per
QALY
Total
costs
Total
costs
Total
QALYs
Total
QALYs
Cases Controls Cases Controls
1 RCT RCT €12,655 €56,608 €39,182 7.8 6.5
2.1 RCT Matched RW €23,821 €100,424 €67,756 7.8 6.4
2.2 RCT Unmatched RW €5,162 €96,720 €89,629 7.8 6.4
3.1 Matched RW Matched RW €11,245 €88,582 €64,846 8.7 6.5
3.2 Matched RW Unmatched RW €-557 €85,096 €86,271 8.7 6.5
3.3 Unmatched RW Unmatched RW €-6,242 €81,231 €95,830 9.4 7.1
Table adapted from Blommestein et al. [12]
ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, RCT data from randomized clinical trials, RW data from real-world
practice
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interest by using observed patient characteristics [27]. PS
scores are then used to match a treatment group to a
comparator group based on patients who have similar
chances (PS scores) of receiving the treatment of interest.
Other applications of the PS score matching technique
include stratification, covariance adjustment, and weight-
ing [27, 28].
Although PS matching techniques are increasingly and
successfully used [26, 29], these techniques are less
attractive when multiple treatment strategies are compared
simultaneously. A better understanding of the benefits and
limitations in practical circumstances of PS matching vs
multivariate risk modeling is still needed [26].
Finally, in case correcting for confounding is ham-
pered (e.g., missing values or a lack of a control group),
data synthesis can be used to model incremental out-
comes. For example, it may be a good option to syn-
thesize efficacy data from an RCT with effectiveness data
from daily clinical practice, especially when an appro-
priate comparator group is lacking [30]. However, it is
important to be aware that there was an initial need for
data from daily practice because patient baseline char-
acteristics may differ between patients treated and not
treated in an RCT.
4.2 Missing Data
Even when a registry is well designed and executed by an
active interdisciplinary collaborative research group, it is to
be expected that missing values on certain variables will
exist. Therefore, only analyzing complete cases is most
likely not possible. Although imputing mean values might
be less of a problem for RCT data, this method is not to be
recommended because the patient population in daily
practice is usually far more heterogeneous. We recommend
using the multiple imputations method because this method
not only imputes missing values but also accounts for the
uncertainty associated with the imputed value by creating
multiple datasets [31]. Missing values are imputed based
on observed variables. To account for the uncertainty of the
predicted variables, each missing value is imputed multiple
times resulting in several complete datasets. The analyses
of the combined datasets produce overall estimates and
standard errors that reflect the uncertainty around the
imputed variables. However, it is important to note that this
method can only be used for missing values that depend on
known and observed variables (i.e., variables missing at
random) [32].
4.3 Insufficient Number of Comparable Patients
Sufficient numbers of patients and follow-up data are
required for conducting a sound economic evaluation
with registry data. This is, however, sometimes difficult
to realize in daily practice. A large difference may exist
between the actual patient population (i.e., the popula-
tion included in the registry) and the analytic patient
population (i.e., the population that met the criteria for
analysis [1]). RCTs usually base the number of patients
included on power calculations and continue including
patients until the desired number has been reached.
This is, however, not possible in daily practice; for
example, if physicians no longer use the alternative
treatment, the analytic population will be small. The
minimal required number of patients also depends on
the extensiveness of the heterogeneity of the real-world
patients, which may not be known in advance. The
option to actively search for extra patients treated with
the drug of interest has to be balanced with a potential
diminishing generalizability.
In PHAROS, we faced confounding by indication,
missing data, as well as a small analytical patient pop-
ulation. First, confounding by indication was present
because the comparator group included relatively more
patients with a worse prognosis compared with the
treatment group [12]. We used PS matching methods to
correct for observed differences in patient and disease
characteristics. After matching, both groups were more
balanced regarding characteristics of re-induction ther-
apy, B symptoms, and disease progression. Table 2
illustrates the variation on outcomes of our scenario
analyses in which we used both matched and unmatched
data.
Second, we encountered a small analytical patient
population in PHAROS. The actual population included
nearly 700 patients with follicular lymphoma. However,
the required analyses were too early for most patients
because the patients did not (yet) receive a second line
of chemotherapy. Therefore, only 14 % of the actual
population was included in the analytic population. To
increase the number of patients, data were obtained from
Hemobase, a multidisciplinary Web-based electronic
patient record in the north-eastern part of the Nether-
lands that collected similar data. Although this increased
the analytic population from 89 to 113 patients, the
number of patients remained small. The rather small and
highly heterogeneous population led to wide confidence
intervals for treatment with rituximab maintenance (e.g.,
OS of matched real-world effects ranged from 1.0 to
3.9 years and costs ranged from -€44,362 to
?€105,977).
Third, because missing data were present for relevant
outcomes (e.g., response rates), the number of patients
included in our analyses reduced even further after apply-
ing PS matching (e.g., N = 51 reduced to N = 43 in the
rituximab group).
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5 The Value of Real-World Economic Evaluations
for Decision Makers
Decision makers often make limited use of evidence from
economic evaluations [33, 34]. There is, however, a higher
chance that decision makers use such evidence if the evi-
dence is accessible (i.e., timeliness and understandability)
and acceptable (i.e., accuracy and validity of research
methods given institutional requirements) [7].
Above all, it is crucial that decision makers realize that
registry data differ from RCT data and that the outcomes of
their economic evaluations should thus be assessed dif-
ferently. This should, however, not be seen as a drawback,
but rather as an important opportunity. Both data sources
complement each other; they allow balancing internal
validity and generalizability and answer different
questions.
The economic evaluation based on PHAROS data
demonstrated these differences by calculating different
scenarios. Table 2 presents these scenarios as well as their
outcomes. We discuss the value of each scenario for
healthcare decision makers regarding whether the research
methods were accessible and acceptable.
Scenario 1 was only based on RCT results; no real-
world data were included in the analyses. Randomization
ensured the internal validity; therefore, the difference
between the intervention group (i.e., patients who received
rituximab maintenance therapy) and the control group (i.e.,
patients who were only observed) could be attributed to the
treatment. In other words, treating patients with rituximab
maintenance therapy costs €12,655 per QALY gained
compared with observation only. This scenario used well-
known conventional methods (RCT data) and may thus be
highly accessible and acceptable to decision makers.
Accessibility and acceptability is ensured by the under-
standability of the results, i.e., economic evaluations based
on trial data are intuitive because conventional methods are
used. This is, however, at the cost of generalizability,
because no data were used from daily practice. The results
do not inform decision makers on the expected costs and
effects in the real-world patient population while this was
the policy issue at stake. As a consequence, none of the
questions raised by decision makers (i.e., to whom and how
is the drug prescribed and what is the real-world cost
effectiveness) can be answered with scenario 1.
In scenarios 2.1 and 2.2, efficacy data from the RCT
were combined with matched and unmatched real-world
cost data, respectively. This resulted in substantial differ-
ences in the estimated costs per QALY gained (€23,821/
QALY for scenario 2.1 and €5,162/QALY for scenario
2.2). Because both scenarios combined RCT data with real-
world data, the interpretation of the outcomes may be more
complicated because it is unclear to whom the results
apply, i.e., trial, real-world patients, or both. In other
words, results are less accessible for decision makers. The
effectiveness estimates are internally valid because they are
based on RCT data, but they do not inform decision makers
on the effectiveness in daily practice. In contrast to sce-
nario 1, both scenarios 2.1 and 2.2 provide information on
real-world costs. It should be noted, however, that the
accuracy of the incremental costs in scenario 2.2 may be
impeded because patients treated and not treated with rit-
uximab maintenance therapy were not comparable and we
did not correct for these differences by using a matching
method. Moreover, it is questionable for whom the ICER is
actually valid (i.e., the efficacy estimates apply to trial
patients while the cost estimates apply to the real-world
patient population). Therefore, both ICERs should be
carefully interpreted.
Scenarios 3.1, 3.2, and 3.3 used real-world data for both
cost and effectiveness estimates. Consequently, the results
are generalizable to the real-world patient population and
applicable to the policy issue at stake. Because decision
makers are less familiar with interpreting real-world data,
these scenarios may be less accessible for decision makers.
It is, therefore, crucial that the methods and results are
extensively reported in an understandable language.
Unmatched data as used in scenarios 3.2 and 3.3 inform
decision makers on the real-world costs and effects, but a
major drawback is that differences cannot be assessed
between cases and controls because the incremental esti-
mates are not sufficiently valid. Both scenarios 3.2 and 3.3
show higher total costs for the control group while the
opposite was expected and shown by the other scenarios.
Although matching methods reduced the analytical popu-
lation, we believe that scenario 3.1 provides the most
accurate and valid results because matching methods were
used for both costs and effects to reduce bias related to
confounding by indication.
Decision makers were interested in real-world outcomes
and, in the Dutch case, required evidence from daily clin-
ical practice to reduce the uncertainty of both real-world
costs and effects of rituximab maintenance therapy. We
believe that the computed ICERs can only be used if the
applied methods are accurate and valid. In other words,
incremental outcomes of economic evaluations can only be
used when cases and controls are comparable or when
appropriate methods are used to correct for differences in
baseline characteristics (scenarios 1 and 3.1). In cases
where baseline characteristics greatly differ between
patient groups and no matching methods have been used,
the outcomes of an economic evaluation should not be
acceptable for decision makers because the incremental
outcomes are not accurate and not valid. We believe that
scenario 3.1 is most valuable to decision makers because
this scenario achieves an appropriate balance between
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generalizability and internal validity. The estimated cost-
effectiveness ratio (€11,245) also provides reassurance to
decision makers that efficacy from the trial can be realized
at favorable costs in the real-world patient population.
However, because a formal decision has not yet been made,
it is currently unknown how decision makers interpreted
and evaluated the outcomes.
6 Further Research Areas for Registry Data
Expensive cancer drugs are increasingly developed for
patient populations stratified by genetic characteristics and
this trend illustrates an increasing role for biochemical,
histological, and genetic markers to aid treatment decisions
[35]. While the PHAROS registry focused on expensive
drugs, registries may also be used to collect information on
biochemical, histological, and genetic markers, which can
be used for economic evaluations of these markers. This
may be an important subject for further research using
registry data.
7 Final Remarks
It is important for decision makers that a drug provides
sufficient value in relation to its costs in daily practice.
Economic evaluations based on real-world data can pro-
vide extremely valuable insights into real-world incre-
mental cost effectiveness [12, 30, 36]. In PHAROS, both
matched and unmatched outcomes seem favorable for the
decision to adopt rituximab maintenance therapy. In other
cases, the variation in outcomes can be much greater and
less favorable than in PHAROS, which necessitates a
careful evaluation of the causes of the conflicting results
between RCT and real-world data. Moreover, it may not
always be possible to develop a feasible model with real-
world data to calculate incremental estimates [19]. We
advocate that incremental estimates (ICERs) should always
be based on matched patients in case patient groups are
incomparable. However, unmatched real-world data are
still valuable for decision makers because they provide
evidence on costs and effects of a treatment in a real-world
setting, although not incremental [18, 19, 34]. Real-world
evidence can also be used to obtain a certain level of
reassurance regarding the extent to which the evidence
from the RCT is applicable to the real-world patient pop-
ulation. It is, however, crucial that decision makers realize
that the outcomes of an economic evaluation based on
registry data should be assessed differently compared with
the outcomes of an economic evaluation based on RCT
data. The need for generalizable outcomes has to be bal-
anced with the need for internally valid outcomes. While
registries are able to provide insight into the use, effec-
tiveness, and costs of a therapy in routine clinical practice
and therefore offer healthcare decision makers with real-
istic expectations for outcomes in real-world patients, it
should be noted that other solutions exist to balance
internal and external validity. For example, pragmatic trials
can include a broad patient population and can thus also
ensure generalizability. Pragmatic trials have the major
advantage of randomizing treatment but are on the other
hand, however, associated with logistical, ethical, and
sample size challenges as well as high resource invest-
ments [37].
In PHAROS, we demonstrated that it was feasible to
conduct a real-world economic evaluation using registry
data. We believed that we provided decision makers with
acceptable and accessible information and showed that the
real-world outcomes confirmed the efficacy of the trial. In
our opinion, this provided reassurance to decision makers
about a drug’s value for money in daily clinical practice.
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